activity of egfr tkis in patients with nsclc with uncommon egfr mutations
Published 3 years ago • 255 plays • Length 2:45Download video MP4
Download video MP3
Similar videos
-
1:21
detectability of uncommon egfr mutations in nsclc: ngs versus pcr
-
0:37
response to systemic anti-cancer therapy in uncommon egfr mutations
-
0:48
assessing efgr tkis in patients with wild-type efgr nsclc
-
1:04
ngs provides improved identification of uncommon egfr mutations over pcr in nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:26
the challenge of treatment resistance in patients with advanced egfr-mutated nsclc
-
1:41
physician perceptions of testing practices in patients with egfr mutated nsclc
-
4:06
afatinib in patients with uncommon egfr mutations
-
20:24
targeted treatment with egfr tkis: front line options
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
1:04
molecular testing in egfr mutant driven nsclc
-
1:41
egfr mutations in patients with lung cancer
-
10:30
tumor clonality in egfr mutation-positive nsclc
-
5:47
egfr tkis for upfront treatment of nsclc
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
2:36
second- and third-generation tkis in egfr-mutated nsclc